Full video transcriptClick to expand
Auto-generated transcript of @forever.fit.kelly's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00Real talk was Tess and Rowan worth it after 10 weeks in my honest opinion. Yes, but you have to be patient for me
- 0:06I didn't notice any visible changes in weeks one through four
- 0:08I did notice some benefits like better muscle recovery after workouts and improved sleep quality at night
- 0:13Then in weeks five six and beyond is when some of the visible changes started happening in terms of body recomposition
- 0:20Leaning out your midsection. I am 45 years old and I finally have abs coming through
- 0:25Overall muscle growth and definition has been incredible on Tessa
- 0:28I am doing the same workouts. I've always done so just 20 minutes a day in my house
- 0:32I am not spending hours in the gym nutrition has also been the same so adding Tessa can be a real game changer for your physique
- 0:39I am super happy that I stuck with it. It will take time
- 0:42So be patient if you have any more questions about my experience
- 0:46Just comment below or DM me and I'm happy to answer any questions and share more about my experience
Tesamorelin and 'hello abs': what 10 weeks actually does
Quick answer
Tesamorelin is a synthetic GHRH analog FDA-approved for visceral fat reduction in HIV-associated lipodystrophy, with its strongest clinical evidence from Falutz et al. (2010, NEJM) in that specific population. Kelly's reported benefits including improved sleep, better recovery, and midsection fat loss are mechanistically plausible but cannot be cleanly attributed to the peptide alone given the absence of controlled baselines, disclosed dosing, or clinical monitoring in her account. Off-label aesthetic use in healthy adults carries real risks including glucose dysregulation and edema that were not disclosed in the video.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Tesamorelin access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 10 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Tesamorelin and 'hello abs': what 10 weeks actually does, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
EGRIFTA (tesamorelin for injection) FDA Prescribing Information
FDA-approved label for tesamorelin (NDA 022505), indicated to reduce excess abdominal fat in HIV patients with lipodystrophy.
FDA
Egrifta (tesamorelin) Original NDA 022505 FDA Approval Letter
FDA approval letter marking the first approved drug for HIV-associated lipodystrophy.
FDA
Emerging pharmacotherapies for obesity: A systematic review
Broad context for new and established obesity-drug categories.
PubMed
Glucagon-like receptor agonists and next-generation incretin-based medications
Current review for incretin-based obesity medications and cardiometabolic effects.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Tesamorelin is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Tesamorelin and 'hello abs': what 10 weeks actually does" from Kelly | Fitness & Biohacking. We read the clip as a Peptide social video fact-checks claim about Tesamorelin, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Tesamorelin is a synthetic GHRH analog FDA-approved for visceral fat reduction in HIV-associated lipodystrophy, with its strongest clinical evidence from Falutz et al.
The reason this review is not generic is the source wording and the canonical claim label "peptides 10 weeks on tesa hello abs proof that patience wins peptok b." In this clip, the useful excerpt is: "Real talk was Tess and Rowan worth it after 10 weeks in my honest opinion." That wording changes the review because it points to Tesamorelin safety, access, evidence, and fit, not a one-size-fits-all protocol.
The source trail for this page is checked against EGRIFTA (tesamorelin for injection) FDA Prescribing Information (2024), Egrifta (tesamorelin) Original NDA 022505 FDA Approval Letter (2010), and Effects of tesamorelin in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial (2010), plus the creator's own wording. Tesamorelin still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
Tesamorelin is a synthetic GHRH analog FDA-approved for visceral fat reduction in HIV-associated lipodystrophy, with its strongest clinical evidence from Falutz et al.
FormBlends verdict
Tesamorelin safety, access, evidence, and fit
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with the Tesamorelin guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Tesamorelin is a synthetic GHRH analog FDA-approved for visceral fat reduction in HIV-associated lipodystrophy, with its strongest clinical evidence from Falutz et al. (2010, NEJM) in that specific population. Kelly's reported benefits including improved sleep, better recovery, and midsection fat loss are mechanistically plausible but cannot be cleanly attributed to the peptide alone given the absence of controlled baselines, disclosed dosing, or clinical monitoring in her account. Off-label aesthetic use in healthy adults carries real risks including glucose dysregulation and edema that were not disclosed in the video.
- Tesamorelin's only FDA approval is for visceral fat in HIV-associated lipodystrophy, per the Falutz et al. 2010 NEJM trials. Off-label use in healthy adults lacks large-scale RCT backing.
- Van Cauter et al. (2000, JAMA) supports the sleep improvement Kelly describes, as GHRH analogs increase slow-wave sleep, which is the most credible specific claim in the video.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Tesamorelin decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Tesamorelin guide, cost path, safety notes, and provider review before acting.
Review TesamorelinWhat You'll Learn
- Tesamorelin's only FDA approval is for visceral fat in HIV-associated lipodystrophy, per the Falutz et al. 2010 NEJM trials. Off-label use in healthy adults lacks large-scale RCT backing.
- Van Cauter et al. (2000, JAMA) supports the sleep improvement Kelly describes, as GHRH analogs increase slow-wave sleep, which is the most credible specific claim in the video.
- Kelly's attribution of results solely to tesamorelin ignores that improved sleep independently reduces cortisol and promotes fat loss, creating at minimum a two-variable confound.
- Compounded tesamorelin is not equivalent to FDA-approved Egrifta. No peer-reviewed equivalency data exists for compounded formulations currently sold through telehealth platforms.
- Spooner et al. (2012, AIDS) documented impaired glucose metabolism as a side effect of tesamorelin. Anyone using this without monitoring fasting glucose and HbA1c is taking an unquantified metabolic risk.
- A 10-week self-reported body recomposition claim with no baseline DEXA, no disclosed dose, and no clinical supervision is not evidence. It is anecdote, and the distinction matters when audiences are making health decisions.
- The 4-6 week lag Kelly describes before visible changes is consistent with clinical trial timelines and is one of the more credible pieces of information in the video.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @forever.fit.kelly actually say?
Kelly claims that after 10 weeks on tesamorelin (which she calls "Tessa"), she developed visible abs at age 45, improved muscle recovery, and slept better, all without changing her workouts or nutrition. She says results didn't show up until weeks five through six, and she describes the outcome as "a real game changer for your physique." To her credit, she repeatedly tells viewers to be patient and doesn't promise overnight results. What she doesn't mention: her dose, whether she was supervised by a clinician, or what her baseline body composition looked like. Those omissions matter a lot when you're talking about a peptide that was FDA-approved for a specific medical condition, not general fat loss in otherwise healthy adults.
Does the science back this up?
Partially, and the distinction is important. Tesamorelin is backed by real clinical evidence, but that evidence is narrow. The short answer is yes, tesamorelin reduces visceral fat, but the research is almost entirely in HIV-positive patients with lipodystrophy, not fit 45-year-old women doing home workouts.
The pivotal FDA-approval trials (Falutz et al., 2010, New England Journal of Medicine) showed statistically significant reductions in visceral adipose tissue (VAT) in HIV patients over 26 weeks. A follow-up analysis (Falutz et al., 2014, Journal of Clinical Endocrinology and Metabolism) confirmed sustained VAT reduction with continued use. These are real findings. But the population studied is so different from Kelly's audience that extrapolating directly is a stretch. Studies in healthy older adults with age-related GH decline are smaller and less definitive. Rudman et al.'s 1990 NEJM work on growth hormone in older men is often cited in this space, but it involved synthetic HGH, not tesamorelin, and has been widely criticized for overstating anti-aging effects.
The sleep and recovery benefits Kelly mentions are plausible. Growth hormone secretagogues can improve slow-wave sleep (Van Cauter et al., 2000, JAMA), which would support the recovery she describes. That part tracks.
What did they get wrong (or right)?
Kelly gets the timeline roughly right, and that's worth acknowledging. She's correct that tesamorelin's effects on body composition are not immediate. The Falutz 2010 data showed meaningful VAT changes appearing around week 8 to 26, so her observation that visible changes started around weeks five to six is plausible, if slightly optimistic.
Where she goes wrong is the attribution problem. She says she kept "nutrition the same" and "the same workouts," implying tesamorelin alone drove her results. That's a significant oversimplification. Body recomposition in a 45-year-old woman is influenced by hormonal status, sleep quality (which she says improved), training consistency, and caloric intake in ways that are genuinely hard to isolate. She has no control condition. This is a classic n=1 confound: she changed at least one variable (the peptide), which itself improved sleep, which affects cortisol, which affects fat storage. Crediting only "Tessa" ignores the cascade.
She also calls it a "game changer for your physique" without any qualification about who this applies to, what supervision is needed, or what the risks are. Side effects including fluid retention, joint pain, and potential effects on glucose metabolism go unmentioned.
What should you actually know?
Tesamorelin is a growth hormone-releasing hormone (GHRH) analog. It works by stimulating the pituitary to release more endogenous growth hormone, which then drives IGF-1 production and promotes lipolysis, particularly in visceral fat. The mechanism is real. The question is whether using it off-label for aesthetic body recomposition in healthy adults is supported by evidence, and the honest answer is: not robustly.
Off-label use is legal when prescribed by a licensed provider, but compounded tesamorelin is not the same as FDA-approved Egrifta. Compounded versions vary in purity and concentration, and no head-to-head equivalency data exists. Anyone considering this should be working with a clinician who has ordered baseline labs including IGF-1, fasting glucose, and HbA1c, since tesamorelin can impair insulin sensitivity (Spooner et al., 2012, AIDS).
- Tesamorelin is FDA-approved only for HIV-associated lipodystrophy.
- Off-label use for general fat loss exists but lacks large-scale RCT support in healthy populations.
- Side effects include edema, arthralgia, and glucose dysregulation.
- Results in Kelly's video cannot be attributed solely to the peptide without a controlled baseline.
- Anyone using this should have ongoing clinical supervision, not just a single consult.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Kelly | Fitness & Biohacking · TikTok creator
11.3K views on this video
10 weeks on Tesa = hello abs 👀. Proof that patience wins. #peptok #biohacking #tesamorelin #tesa #fitmom
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about tesamorelin's only fda approval?
Tesamorelin's only FDA approval is for visceral fat in HIV-associated lipodystrophy, per the Falutz et al. 2010 NEJM trials. Off-label use in healthy adults lacks large-scale RCT backing.
What does the video say about van cauter et al. (2000, jama) supports the sleep improvement?
Van Cauter et al. (2000, JAMA) supports the sleep improvement Kelly describes, as GHRH analogs increase slow-wave sleep, which is the most credible specific claim in the video.
What does the video say about kelly's attribution of results solely to tesamorelin ignores?
Kelly's attribution of results solely to tesamorelin ignores that improved sleep independently reduces cortisol and promotes fat loss, creating at minimum a two-variable confound.
What does the video say about compounded tesamorelin?
Compounded tesamorelin is not equivalent to FDA-approved Egrifta. No peer-reviewed equivalency data exists for compounded formulations currently sold through telehealth platforms.
What does the video say about spooner et al. (2012, aids) documented impaired glucose metabolism as?
Spooner et al. (2012, AIDS) documented impaired glucose metabolism as a side effect of tesamorelin. Anyone using this without monitoring fasting glucose and HbA1c is taking an unquantified metabolic risk.
What does the video say about a 10-week self-reported body recomposition claim with no baseline dexa,?
A 10-week self-reported body recomposition claim with no baseline DEXA, no disclosed dose, and no clinical supervision is not evidence. It is anecdote, and the distinction matters when audiences are making health decisions.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Kelly | Fitness & Biohacking, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.